Nexeo Solutions, Inc. (NASDAQ:NXEO)
Nexeo Solutions, Inc. distributes chemicals and plastics products. The company’s line of business consists of Chemicals, Plastics and Environmental Services. It operates primarily in North America, Europe, the Middle East and Africa and Asia. Nexeo Solutions, Inc. is based in The Woodlands, Texas.
Nexeo Solutions, Inc. (NASDAQ:NXEO)’s Financial Overview
Nexeo Solutions, Inc. (NASDAQ) declined -3.46% yesterday to close its trading session at $9.21. The company has 1 year Price Target of $11.75. Nexeo Solutions, Inc. has 52-Week high of $12.64 and 52-Week Low of $7.93. The stock touched its 52-Week High on 12.64 and 52-Week Low on 7.93. The stock traded with the volume of 983645 shares yesterday. The firm shows the market capitalization of $819.78 Million.
Nexeo Solutions, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.27/share against the analyst consensus estimate of $0.2/share. The difference between the actual and expected EPS is $0.07 a share with a surprise factor of 35%.
The firm is trading with SMA20 of 0.46 Percent, SMA50 of 2.02 Percent and SMA200 of -6.36 percent. Nexeo Solutions, Inc. has P/S value of 0.2 while its P/B value stands at 0.87. Similarly, the company has Return on Assets of 1.3 percent, Return on Equity of 3.6 percent and Return on Investment of 4.7 Percent. The company shows Gross Margin and Operating Margin of 11.4 percent and 2.4 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 2 analysts offering 12-month price forecasts for Nexeo Solutions Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +8.58% increase from the last price of 9.21.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
Orgenesis Inc. (NASDAQ:ORGS)
Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD.
Orgenesis Inc. (NASDAQ:ORGS)’s Financial Outlook
The 1 analysts offering 12-month price forecasts for Orgenesis Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +100.40% increase from the last price of 4.99.
Orgenesis Inc. is estimated to report earnings on 02/27/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.21.
According to Zacks Investment Research, Orgenesis Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 0.71% and closed its last trading session at $4.99. The company has the market capitalization of $81.34 Million. The stock has 52-week high of $16.8 and 52-Week low of $3.87. The firm touched its 52-Week high on 16.80 and 52-Week low on 3.87. The company has volume of 30140 shares. The company has a total of 16.3 Million shares outstanding.
The company has YTD performance of 6.62 percent. Beta for Orgenesis Inc. stands at 1.39 while its ATR (average true range) is 0.35. The company has Weekly Volatility of 9.86%% and Monthly Volatility of 6.31%%.
Orgenesis Inc. has distance from 20-day Simple Moving Average (SMA20) of 4.06%, Distance from 50-Day Simple Moving Average of -0.13 percent and Distance from 200-Day Simple Moving Average of -25.92%.
The Company currently has ROA (Return on Assets) of -28.5 percent, Return on Equity (ROE) of -63.6 Percent and Return on Investment (ROI) of -39.9% with Gross margin of 43.8 percent and Operating & Profit margin of -49.5% and -87.2% respectively.